Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes

Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes - Efficacy and safety of hypoglycemic agents in nonalcoholic fatty liver disease with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045572

Enrollment

100

Registered

2021-09-27

Start date

2021-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease with type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)age =>20 years 2)Type 2 diabetes 3)Patients with NAFLD diagnosed by clinical data 4)Patients provided with informed consent

Exclusion criteria

Exclusion criteria: 1) daily alcohol consumption =>30 g for males and =>20 g for females 2) other chronic liver diseases, such as viral hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, Wilson disease, and hemochromatosis 3) pregnancy and lactation 4) Others judged unsuitable by researchers

Design outcomes

Primary

Measure	Time frame
Changes in liver stiffness 1 year after administration from baseline	—

Countries

Japan

Contacts

Public ContactTaeang Arai

Nippon Medical School Division of Gastroenterology and Hepatology

taeangpark@yahoo.co.jp03-3822-2131

Outcome results